Journal of Thoracic Oncology

简称 J THORAC ONCOL ·UNITED STATES ·出版周期 Monthly ·年均收录 206 篇

20.8

最新影响因子

8.40%

自引率

较易

投稿难度

一般,3-6周

审稿周期

期刊简介

Journal of Thoracic Oncology是一本专注于胸部肿瘤学的国际学术期刊，ISSN号为1556-0864，由Elsevier出版社出版，出版地为美国，出版周期为月刊。该期刊的影响因子较高，属于SCI收录期刊，并且在中科院分区中通常位于医学或肿瘤学领域的较高分区。期刊内容涵盖肺癌、胸腺瘤、食管癌等胸部肿瘤的基础与临床研究，发文特点包括原创研究、综述、病例报告和国际指南，尤其注重多学科交叉研究和转化医学。期刊质量较高，审稿严格，但作为非OA期刊，部分内容可能需要订阅才能获取。风险方面，由于竞争激烈，投稿难度较大，且版面费可能较高。总体而言，该期刊是胸部肿瘤学领域的重要学术平台，适合高质量研究成果的发表。

影响因子趋势

近期发表

Incorporation of Nonanatomic Histologic Factors Into a Staging System for Lung Cancer: Now Is the Time? 2026-09-04

Letter to the Editor Regarding “Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial” 2026-09-04

Corrigendum to ‘Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial’ [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564] 2026-06-23

Implications of Clinical and Genetic Management of Subjects With BAP1 Germline Variants 2026-09-04

Re-Evaluating the Impact of KRAS Mutations in Stage III Nonsquamous NSCLC Treated With Chemoradiation and Immunotherapy 2026-09-04

Board of Directors 2026-09-04

Table of Contents 2026-09-04

In This Issue 2026-09-04

Meeting Announcements 2026-09-04

In the Era of Neoadjuvant Chemo-Immunotherapy for Resectable Locally Advanced Stage III NSCLC, Neoadjuvant Chemoradiotherapy Is No Longer a Standard of Care 2026-09-04